ABIVAX Société Anonyme’s (NASDAQ:ABVX) Lock-Up Period Set To Expire on April 17th

ABIVAX Société Anonyme’s (NASDAQ:ABVX) lock-up period is set to expire on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its IPO on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. After the end of ABIVAX Société Anonyme’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analysts Set New Price Targets

Separately, Morgan Stanley increased their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the company an “equal weight” rating in a research report on Thursday, April 11th.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX opened at $14.73 on Wednesday. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02. The company has a 50-day moving average of $13.92.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several large investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $249,000. Capstone Investment Advisors LLC acquired a new stake in ABIVAX Société Anonyme during the fourth quarter worth $618,000. Ghisallo Capital Management LLC acquired a new stake in ABIVAX Société Anonyme during the fourth quarter worth $642,000. Point72 Asset Management L.P. bought a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $4,488,000. Finally, Citadel Advisors LLC acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at $7,842,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.